Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXTBiotechnology
+$0.46 today
- Market cap
- $89.11M
- Beta
- 1.05
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$0.67
Volume 0.61M
Average 0.12M
LIXT Deferred Revenue
Payments received for goods or services the company will deliver within the next year.
Lixte Biotechnology Holdings, Inc.NASDAQ: LIXT
Deferred Revenue · Q1 FY2026 · quarter ended Mar 2026
Deferred revenue broadly unchanged from a year ago
Deferred revenue stood at $238.44K at the end of Q1 FY2026, down 1.7% from a year earlier and up 2.7% from the prior quarter. Over 3 fiscal years it compounded at +12.0% a year.
Context
- Deferred revenue amounted to 2.2% of total assets at the end of Q1 FY2026, down 13.8 pp from a year earlier.
- Deferred revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether deferred revenue keeps falling in the next quarterly balance sheet after a -1.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Deferred Revenue history
USD · from the balance sheet
- Latest · FY2025
- 232.14K USD
- Year-over-year change
- -1.3%
| Period | Period end | Deferred Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 232.14K | -1.3% |
| FY2024 | 2024-12-31 | 235.08K | +49.6% |
| FY2023 | 2023-12-31 | 157.1K | -4.8% |
| FY2022 | 2022-12-31 | 165.02K | — |
| FY2021 | 2021-12-31 | 0 | — |
Deferred Revenue vs competitors
How LIXT compares with its peers on the latest reported figures
- LIXT's Mar 2026 deferred revenue of $238.44K is the highest of the 2 companies compared; the peer median is $0.
- Deferred revenue amounts to 2.2% of total assets for LIXT, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $238.44K | -1.7% | +12.0% | 2.2% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding LIXT) | $0 | — | — | 0.0% | |
Competitors are the stored peer set for LIXT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Lixte Biotechnology Holdings, Inc.
NASDAQ:LIXT
Intrinsic Alpha fair value
Locked
Current Price
$7.21
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.